Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Open accessThe DOI matches its Crossref record; 141 of the 145 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio–metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP‐1 receptor agonists, including liraglutide, semaglutide, and tirzepatide (dual GIP/GLP agonists), have revolutionised the field of obesity pharmacotherapy by facilitating substantial weight loss, achieving an average reduction of 9% with liraglutide, up to 15% with semaglutide, and 18% with tirzepatide [11, 12].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a critical consideration, as GLP-1RA treatment duration in patients with obesity is highly variable, ranging up to 24 months depending on weight loss goals.18”
From GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis (2025) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs consistently demonstrate significant weight loss (mean reductions of 7–9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid profiles in both diabetic and non-diabetic populations (5–7, 10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“There were no significant differences in hospitalization rates for non-fatal myocardial infarction, non-fatal stroke, and heart failure between the liraglutide and placebo groups [89].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 21×
“The first approach aimed at prolonging the hal -life of GLP-1 y i h bitin its degradation by DPP-4 through the d vel pment of DPP-4 inhibitors.”
BackgroundInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 2×
“9 kg) resulted in smaller changes [65].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613 · cited 2×
“sclerosis, heart failure [14], and atrial fibrillation [15], while metabolic complications in-”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064 · cited 2×
“clude T2DM [16,17], dyslipidemias [18], hyperuricemia, and metabolic syndrome [19].”
BackgroundChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“However, long-term safety data for these medications are not available [40].”
BackgroundGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 3×
“These medications are still available to clinicians as GLP-1 receptor agonists (GLP1-RAs) [10].”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“basal insulin and/or long-term therapy [63].”
BackgroundObesity Evaluation and Treatment: Expert Committee Recommendations
Barlow, S. E., & Dietz, W. H. (1998) · Pediatrics · doi:10.1542/peds.102.3.e29 · Cited by 1,565 · cited 1×
“Additionally, obesity is associated with osteoarticular complications such as arthrosis [9], venous and lymphatic circulatory disorders [25], endocrine complications including hyperinsulinism, hypercorticism, hypothyroidism, and hypogonadism [26,27], and oncological conditions such as endometrial [28,29] and breast ca…”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 1×
“4 mg administered subcutaneously once a week became another FDA-approved (GLP1-RA) for chronic weight management [43].”
BackgroundDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Obesity: definition, comorbidities, causes, and burden.
Apovian, C. M. (2016) · PubMed · Cited by 1,384
Danaei, G., Vander Hoorn, S., Lopez, A. D., Murray, C. J., & Ezzati, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67725-2 · Cited by 1,367
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“which is 2-aminoisobutyric acid (AIB), aiming to inhibit degradation by DPP-4 [49].”
BackgroundRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · cited 1×
“GLP-1 secretion from the gut seems to be impaired in obese subjects, suggesting a role in the pathophysiology of obesity [57].”
BackgroundTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Prospective Study of Body Mass Index, Weight Change, and Risk of Adult-onset Asthma in Women
Camargo, C. A., Weiss, S. T., Zhang, S., Willett, W. C., & Speizer, F. E. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2582 · Cited by 855 · cited 1×
“R spiratory complications such as mixed ventilatory dysfunction, Pickwick syndrome, sleep apnea syndrome [20], asthma [21], and digestive complications such as gastroesophageal”
Backgroundle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Calle, E. E., & Thun, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207751 · Cited by 769 · cited 1×
“Additionally, obesity is associated with osteoarticular complications such as arthrosis [9], venous and lymphatic circulatory disorders [25], endocrine complications including hyperinsulinism, hypercorticism, hypothyroidism, and hypogonadism [26,27], and oncological conditions such as endometrial [28,29] and breast ca…”
BackgroundFuture directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750 · cited 2×
“Various signals from the peripheral organs send information to the central nervous system about the nutritional status [52,53].”
BackgroundOnce-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730
Sjöström, C. D., Lissner, L., Wedel, H., & Sjöström, L. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00436.x · Cited by 693 · cited 2×
“Common cardiovascular complications include hypertension [13], athero-”
BackgroundDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592 · cited 2×
“[99]. liraglutide did not significantly reduce heart failure hospitalizations in the LEADER trial [89], and there were more serious cardiac adverse events in patients with chronic heart failure with reduced left ventricular ejection fraction treated with liraglutide 1.8 mg once daily than placebo in a study of left ve…”
BackgroundInfluentialBuse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 1×
“Exercise and liraglutide therapy together promoted healthy weight loss maintenance more than either therapy alone [83].”
BackgroundRisk factors associated with symptoms of gastroesophageal reflux
Locke, G. R., Talley, N. J., Fett, S. L., Zinsmeister, A. R., & Melton, L. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00121-7 · Cited by 522 · cited 1×
“reflux [22,23], hiatal hernia, gallstones, and non-alcoholic fatty liver [24] are also often observed in obese individuals.”
BackgroundNormal fasting plasma glucose levels and type 2 diabetes in young men
Tirosh, A., Shai, I., Tekes-Manova, D., Israeli, E., Pereg, D., Shochat, T., Kochba, I., & Rudich, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050080 · Cited by 508 · cited 2×
“clude T2DM [16,17], dyslipidemias [18], hyperuricemia, and metabolic syndrome [19].”
BackgroundBlevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448
Kim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 446
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000200416.65370.a0 · Cited by 435
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications
Sarma, S., Sockalingam, S., & Dash, S. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14290 · Cited by 435 · cited 1×
“Cutaneous complications like bacterial and fungal infections [35] and mental disorders such as depression, binge eating disorder, and anxiety disorders [36,37] have also been reported in obese individuals.”
BackgroundBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 2×
“to play a minor and temporary role [58].”
BackgroundAn overview of links between obesity and mental health
Avila, C., Holloway, A. C., Hahn, M. K., Morrison, K. M., Restivo, M., Anglin, R., & Taylor, V. H. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0164-9 · Cited by 366 · cited 1×
“Cutaneous complications like bacterial and fungal infections [35] and mental disorders such as depression, binge eating disorder, and anxiety disorders [36,37] have also been reported in obese individuals.”
BackgroundTsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346
Russell-Jones, D., Cuddihy, R. M., Hanefeld, M., Kumar, A., González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 339
Kadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
Point: Visceral Adiposity Is Causally Related to Insulin Resistance
Lebovitz, H. E., & Banerji, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2322 · Cited by 328 · cited 2×
“Central adiposity, as indicated by increased waist circumference [2] and other measures, can predict the cardiometabolic risk that cannot be identified by BMI alone.”
BackgroundEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
Liraglutide for weight management: a critical review of the evidence
Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311 · cited 1×
“liraglutide is effective in inducing and sustaining weight loss in obese patients, with the added benefit of improved glycemic control [82].”
BackgroundThe defence of body weight: a physiological basis for weight regain after weight loss
Sumithran, P., & Proietto, J. (2013) · Clinical Science · doi:10.1042/cs20120223 · Cited by 310 · cited 1×
“Historically, short-term weight loss medications such as phentermine, benzphetamine, and diethylpropion were approved for use over several weeks in the 1960s [39].”
BackgroundThe structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292 · cited 1×
“Exendin-4 was found to display similar activity to GLP-1 but with a markedly longer half-life (2–4 h) because of its enhanced resistance to DPP-4 attributed to the replacement of Ala-8 by Gly-8 at the cleavage site [45] (Figure 4).”
BackgroundRiddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Gastrointestinal Complications of Obesity
Camilleri, M., Malhi, H., & Acosta, A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.052 · Cited by 269 · cited 1×
“reflux [22,23], hiatal hernia, gallstones, and non-alcoholic fatty liver [24] are also often observed in obese individuals.”
BackgroundShaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255
Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence?
Lean, M. E. J., & Malkova, D. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.220 · Cited by 253 · cited 1×
“A hypocaloric diet that causes weight loss leads to a decrease in anorexigenic hormones such as glucagon-like peptide-1 (GLP-1), amylin, cholecystokinin, and PYY while increasing orexigenic hormones such as ghrelin [42].”
BackgroundRosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Rapid development of tolerance to the behavioural actions of cholecystokinin
Crawley, J. N., & Beinfeld, M. C. (1983) · Nature · doi:10.1038/302703a0 · Cited by 243 · cited 2×
“Despite the exploration of the potential therapeutic utility of these peripheral signals, including the use of incretins, a group of metabolic hormones that lower blood sugar levels by increasing insulin secretion from the pancreas, inhibiting the secretion of glucagon, and reducing nutrient absorption, no successful…”
BackgroundMonami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.044 · Cited by 243 · cited 1×
“These conditions indicate the risk of developing terminal complications such as type 2 diabetes mellitus (T2DM), nonalcoholic steatohepatitis, and cardiovascular disease [11].”
BackgroundDavies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Weight control and physical activity in cancer prevention
Bianchini, F., Kaaks, R., & Vainio, H. (2002) · Obesity Reviews · doi:10.1046/j.1467-789x.2002.00046.x · Cited by 223
Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Zhang, X., Belousoff, M. J., Zhao, P., Kooistra, A. J., Truong, T. T., Ang, S. Y., Underwood, C. R., Egebjerg, T., Šenel, P., Stewart, G. D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.020 · Cited by 222
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217 · cited 1×
“liraglutide’s pharmacokinetic properties allow for 24 h glycemic management with a single dose, owing to metabolic stabilization and reduced renal filtration that slow down release from the injection site and eliminate the medication more slowly [84].”
Backgroundon behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210 · cited 1×
“8 mg daily, but it was mostly mild and transient [77,78].”
BackgroundAn overview of GLP-1 agonists and recent cardiovascular outcomes trials
Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137186 · Cited by 194 · cited 1×
“As a result, recommendations prioritize GLP-1 RA treatment for individuals with atherosclerotic vascular disease (such as previous CV events) [64].”
BackgroundPannacciulli, N., Le, D. S. N. T., Salbe, A. D., Chen, K., Reiman, E. M., Tataranni, P. A., & Krakoff, J. A. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.035 · Cited by 182 · cited 2×
“Various signals from the peripheral organs send information to the central nervous system about the nutritional status [52,53].”
BackgroundDejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179 · cited 1×
“However, patients who received liraglutide showed lower hypoglycemic events, bolus and total insulin doses, body weight, and increased heart rate [85].”
BackgroundAhrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Mechanick, J. I., Garber, A. J., Handelsman, Y., Garvey, W. T., Beir, D. M., Bohannon, N. J. V., Bray, G. A., Bush, M. A., Evans, J. G., Hurley, D. L., et al. (2012) · Endocrine Practice · doi:10.4158/ep12160.ps · Cited by 160
Effect of family history, obesity and exercise on breast cancer risk among postmenopausal women
Carpenter, C. L., Ross, R. K., Paganini‐Hill, A., & Bernstein, L. (2003) · International Journal of Cancer · doi:10.1002/ijc.11186 · Cited by 145 · cited 1×
“Additionally, obesity is associated with osteoarticular complications such as arthrosis [9], venous and lymphatic circulatory disorders [25], endocrine complications including hyperinsulinism, hypercorticism, hypothyroidism, and hypogonadism [26,27], and oncological conditions such as endometrial [28,29] and breast ca…”
BackgroundBolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144
Metabolic and health complications of obesity.
Grundy, S. M., & Barnett, J. (1990) · PubMed · Cited by 141
Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen‐Bartmer, I., Guo, H., & Aronson, R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12121 · Cited by 139
Body mass index and patterns of mortality among Seventh-day Adventist men.
Lindsted, K. D., Tonstad, S., & Kuzma, J. W. (1991) · PubMed · Cited by 137
Does severe venous insufficiency have a different etiology in the morbidly obese? Is it venous?
Padberg, F. T., Cerveira, J. J., Lal, B. K., Pappas, P. J., Varma, S., & Hobson, R. W. (2003) · Journal of Vascular Surgery · doi:10.1067/mva.2003.61 · Cited by 134 · cited 1×
“Additionally, obesity is associated with osteoarticular complications such as arthrosis [9], venous and lymphatic circulatory disorders [25], endocrine complications including hyperinsulinism, hypercorticism, hypothyroidism, and hypogonadism [26,27], and oncological conditions such as endometrial [28,29] and breast ca…”
BackgroundRosenstock, J., Guerci, B., Hanefeld, M., Gentile, S., Aronson, R., Tinahones, F. J., Roy-Duval, C., Souhami, E., Wardecki, M., Ye, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0014 · Cited by 133
Kadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00187-5 · Cited by 131
Rosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.012 · Cited by 130
Baig, M. S., Banu, A., Zehravi, M., Rana, R., Burle, S. S., Khan, S. L., Islam, F., Siddiqui, F. A., Massoud, E. E. S., Rahman, M. H., et al. (2022) · Life · doi:10.3390/life12071054 · Cited by 125 · cited 1×
“Cutaneous complications like bacterial and fungal infections [35] and mental disorders such as depression, binge eating disorder, and anxiety disorders [36,37] have also been reported in obese individuals.”
BackgroundSelf-citationWysham, C., Bergenstal, R., Malloy, J., Yan, P., Walsh, B., Malone, J., & Taylor, K. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03301.x · Cited by 118
O'Neil, P. M., Aroda, V. R., Astrup, A., Kushner, R., Lau, D. C. W., Wadden, T. A., Brett, J., Cancino, A., Wilding, J. P. H., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12963 · Cited by 115
New horizons. A new paradigm for treating to target with second-generation obesity medications
Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab848 · Cited by 110 · cited 3×
“progression of cardiometabolic disease towards these severe consequences [12].”
BackgroundInfluentialMonami, M., Dicembrini, I., Nardini, C., Fiordelli, I., & Mannucci, E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.010 · Cited by 106 · cited 1×
“While these risks have not been confirmed through completed clinical trials, continued vigilance is required [91,92].”
BackgroundDiamant, M., Van Gaal, L., Stranks, S., Guerci, B., MacConell, L., Haber, H., Scism-Bacon, J., & Trautmann, M. (2012) · Diabetes Care · doi:10.2337/dc11-1233 · Cited by 96
When Two Pandemics Meet: Why Is Obesity Associated with Increased COVID-19 Mortality?
Lockhart, S. M., & O’Rahilly, S. (2020) · Med · doi:10.1016/j.medj.2020.06.005 · Cited by 93 · cited 1×
“Moreover, obesity is linked to an increased risk of hospitalization, the need for intubation and ventilation, and the risk of death in cases of COVID-19 and 2009 H1N1 [38].”
BackgroundExenatide efficacy and safety: a systematic review
Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02790.x · Cited by 88 · cited 2×
“The synthetic version of exendin-4 (exenatide) was approved by FDA in 2005 in the parenteral form to improve glycemic control in adults with T2DM as an adjunct to diet and exercise [46].”
BackgroundMild Renal Impairment and the Efficacy and Safety of Liraglutide
Davidson, J. A., Brett, J., Falahati, A., & Scott, D. (2010) · Endocrine Practice · doi:10.4158/ep10215.or · Cited by 88
McLaughlin, T., Abbasi, F., Kim, H.-S., Lamendola, C. A., Schaaf, P., & Reaven, G. M. (2001) · Metabolism · doi:10.1053/meta.2001.24210 · Cited by 87 · cited 1×
“Additionally, obesity is associated with osteoarticular complications such as arthrosis [9], venous and lymphatic circulatory disorders [25], endocrine complications including hyperinsulinism, hypercorticism, hypothyroidism, and hypogonadism [26,27], and oncological conditions such as endometrial [28,29] and breast ca…”
BackgroundMoon, H.-S., Chamberland, J. P., Diakopoulos, K. N., Fiorenza, C. G., Ziemke, F., Schneider, B., & Mantzoros, C. S. (2011) · Diabetes Care · doi:10.2337/dc10-0518 · Cited by 86 · cited 2×
“Despite the exploration of the potential therapeutic utility of these peripheral signals, including the use of incretins, a group of metabolic hormones that lower blood sugar levels by increasing insulin secretion from the pancreas, inhibiting the secretion of glucagon, and reducing nutrient absorption, no successful…”
BackgroundWong, C., Lee, M. H., Yaow, C. Y. L., Chin, Y. H., Goh, X. L., Ng, C. H., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609110 · Cited by 86
Garvey, W. T. (2013) · Endocrine Practice · doi:10.4158/ep13263.ra · Cited by 84 · cited 3×
“Additionally, obesity is associated with osteoarticular complications such as arthrosis [9], venous and lymphatic circulatory disorders [25], endocrine complications including hyperinsulinism, hypercorticism, hypothyroidism, and hypogonadism [26,27], and oncological conditions such as endometrial [28,29] and breast ca…”
BackgroundLixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
Christensen, M., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · PubMed · Cited by 84
Cheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82 · cited 1×
“Furthermore, liraglutide has shown significant improvements in insulin action, cardiovascular disease (CVD) risk, weight reduction (including waist circumference), and reproductive function, including increased pregnancy rates in overweight or obese PCOS women [87].”
BackgroundGao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935823 · Cited by 81
Oral semaglutide in type 2 diabetes
Anderson, S. L., Beutel, T. R., & Trujillo, J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107520 · Cited by 79 · cited 2×
“Maintenance of weight loss over time was examined in the STEP-4 trial, which demonstrated that semaglutide leads to continuous weight loss [44].”
BackgroundGuja, C., Frías, J. P., Somogyi, A., Jabbour, S., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 78
Steinberg, W. M., Rosenstock, J., Wadden, T. A., Donsmark, M., Jensen, C. B., & DeVries, J. H. (2017) · Diabetes Care · doi:10.2337/dc16-2684 · Cited by 76 · cited 1×
“A review of amylase/lipase activity levels and acute pancreatitis events in the SCALE weight management trials found that there were reversible, dose-independent increases in amylase/lipase activity that were unrelated to baseline characteristics and did not predict the occurrence of acute pancreatitis and possibly ga…”
BackgroundMetabolic and health complications of obesity
(1990) · Disease-a-Month · doi:10.1016/0011-5029(90)90015-j · Cited by 73 · cited 2×
“clude T2DM [16,17], dyslipidemias [18], hyperuricemia, and metabolic syndrome [19].”
BackgroundAlorabi, M., Cavalu, S. D., Al-Kuraishy, H. M., Al-Gareeb, A. I., Mostafa‐Hedeab, G., Negm, W. A., Youssef, A., El-Kadem, A. H., Saad, H. M., & Batiha, G. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113225 · Cited by 67 · cited 1×
“Genitourinary complications such as menstrual disorders, reduced fertility, obstetric complications, polycystic ovary [32,33], gynecomastia, urinary incontinence, and impaired renal function [34] have also been associated with obesity (Figure 2).”
BackgroundSelf-citationDavies, M. J., Kela, R., & Khunti, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66 · cited 1×
“8 mg daily, but it was mostly mild and transient [77,78].”
BackgroundAn evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65 · cited 1×
“Serious adverse effects are uncommon, and the major limitations are cost and the need for daily injections [101].”
BackgroundAssociation of non-alcoholic fatty liver disease and polycystic ovarian syndrome
Asfari, M. M., Sarmini, M. T., Baidoun, F., Al‐Khadra, Y., Ezaizi, Y., Dasarathy, S., & McCullough, A. J. (2020) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2019-000352 · Cited by 65 · cited 1×
“Genitourinary complications such as menstrual disorders, reduced fertility, obstetric complications, polycystic ovary [32,33], gynecomastia, urinary incontinence, and impaired renal function [34] have also been associated with obesity (Figure 2).”
BackgroundObesity hypoventilation syndrome
Shetty, S., & Parthasarathy, S. (2015) · Current Pulmonology Reports · doi:10.1007/s13665-015-0108-6 · Cited by 63
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63 · cited 1×
“Thyroid C-cell tumors have been observed in rodents but not humans [90].”
BackgroundHughes, S., & Neumiller, J. J. (2020) · Clinical Diabetes · doi:10.2337/cd19-0079 · Cited by 63
Garber, A. J. (2010) · PubMed · Cited by 58
Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., Öhman, P., & on behalf of the DURATION‐NEO‐2 study investigators (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12908 · Cited by 57
Wang, L. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s358989 · Cited by 56 · cited 1×
“moiety through a spacer in order to bind albumin and hence diminish renal clearance [50] (Figure 8).”
BackgroundNexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51
Román, G. (2015) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2015.64 · Cited by 44
Oral semaglutide for the treatment of type 2 diabetes
Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1552258 · Cited by 44 · cited 2×
“parable to the once-weekly subcutaneous preparation was approved [61,62].”
BackgroundDrug Treatment of Obesity: Established and Emerging Therapies
Isidro, M., & Cordido, F. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709788452739 · Cited by 43
Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 38
Meneilly, G. S., Roy-Duval, C., Alawi, H., Dailey, G., Bellido, D., Trescoli, C., Manrique Hurtado, H., Guo, H., Pilorget, V., Perfetti, R., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2143 · Cited by 38
Zhang, P., Liu, Y., Ren, Y., Bai, J., Zhang, G., & Cui, Y. (2019) · African Health Sciences · doi:10.4314/ahs.v19i3.35 · Cited by 37 · cited 1×
“A systematic review and meta-analysis concluded that liraglutide is effective and safe for weight loss in obese, non-diabetic individuals [86].”
BackgroundTilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
Cavalu, S. D., Popa, A., Bratu, I., Borodi, G., & Maghiar, A. M. (2015) · Biological Trace Element Research · doi:10.1007/s12011-015-0361-0 · Cited by 31 · cited 1×
“reflux [22,23], hiatal hernia, gallstones, and non-alcoholic fatty liver [24] are also often observed in obese individuals.”
BackgroundSelf-citationSullivan, S. D., Alfonso‐Cristancho, R., Conner, C., Hammer, M., & Blonde, L. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-12 · Cited by 28 · cited 1×
“Therefore, our analysis indicates that liraglutide plus glimepiride is a more effective treatment than rosiglitazone plus glimepiride in terms of projected rates of death, diabetes complications, and long-term healthcare expenditures, using data from LEAD-1 and epidemiologic evidence from the diabetes CORE model [79].”
MethodPhilis-Tsimikas, A., Wysham, C. H., Hardy, E., Han, J., & Iqbal, N. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.012 · Cited by 25
Albiglutide: a unique GLP-1 receptor agonist
Rendell, M. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1240780 · Cited by 23 · cited 2×
“DPP-4 degradation was diminished through a Gly8Ala mutation at the cleavage site of the GLP-1 molecule [51] (Figure 9).”
BackgroundOverweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience
Wilson, P. W. F., D'Agostino, R. B., Sullivan, L., Parise, H., & Kannel, W. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1867 · Cited by 22 · cited 2×
“sclerosis, heart failure [14], and atrial fibrillation [15], while metabolic complications in-”
BackgroundCardiovascular Effects of Liraglutide
Mikhail, N. E. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180507152620 · Cited by 17 · cited 1×
“However, some studies suggest that liraglutide may be detrimental to patients with severe heart failure, primarily due to increased heart rate [88].”
BackgroundEgan, J. M., & Chia, C. W. (2014) · Diabetes · doi:10.2337/db13-1909 · Cited by 12 · cited 1×
“While these risks have not been confirmed through completed clinical trials, continued vigilance is required [91,92].”
BackgroundEffects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1234608 · Cited by 10
Wysham, C., Rosenstock, J., Vetter, M. L., Wang, H., Hardy, E., & Iqbal, N. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000773 · Cited by 5
Research works printed but not linked: 3
- Al-Omar M.A. Al-Suwailem A.K. Al-Tamimi A.S. Al-Suhibani M.S. Safety and mechanism of action of orlistat (tetrahydrolipstatin) as the first local antiobesity drug J. Appl. Sci. Res. 2006 2 205 208
- Kanwal S. AlEmadi E.A. Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Non diabetic, individuals with obesity: A Comprehensive Systematic Review Middle East J. Fam. Med. 2021 19 72 83
- Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet] Canadian Agency for Drugs and Technologies in Health Ottawa, ON, Canada 2019 31305971
Cited by
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
“Furthermore, nasopharyngitis and headaches associated with injections may occasionally occur [107].”
Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., et al. (2025) · Diabetes Care · doi:10.2337/dc24-1678 · Cited by 208
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
“3,4 The safety of GLP-1RAs has been confirmed by large-scale randomized trials, usually with cardiovascular primary endpoints.”
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Galli, M., Benenati, S., Laudani, C., Simeone, B., Sarto, G., Ortega‐Paz, L., Rocco, E., Bernardi, M., Spadafora, L., D’Amario, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.027 · Cited by 140
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Metadata
- Authors
- Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S.
- Affiliations
- University of Oradea (RO)
- University of Kaiserslautern (DE)
- Zagazig University (EG)
- Corresponding author
- Cavalu, Simona
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-21
- Volume
- 24
- Issue
- 13
- Pages
- 10449
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10341852
- OpenAlex
- W4381618228
- Semantic Scholar
- f13196d495574d64dbe2e547bd587bb48816b847
- Cited by
- 280
- References
- 145
- Citations by year
- 2026: 70 · 2025: 131 · 2024: 67 · 2023: 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Oradea
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, weight loss, type 2 diabetes, hyperglycemia, insulin sensitivity, blood pressure, cardioprotection, renal protection, obesity-related comorbidities, long-term safety, non-diabetic patients
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Peptides, Weight Loss, Randomized Controlled Trials as Topic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.